Famisol Injection

Adult administration

Total amino acids should be administered via intravenous drip at a maximum dosage of 1-1.5 g per kg of body weight per day. The infusion rate is recommended to be a concentration of about 10 g of total amino acids over 60 minutes, with a principle of administering 30-40 drops over 1 minute.

Child administration

In pediatric cases, the dosage and infusion rate should be appropriately adjusted for administration.

This medication must be used according to the doctor’s instructions. It should not be administered to patients with severe renal dysfunction or high blood urea nitrogen levels, nor to patients with metabolic disorders of amino acids that are not related to liver dysfunction. It must also be avoided in patients with metabolic disorders related to nitrogen utilization, patients with cardiac failure, and patients with pulmonary edema. Patients with little or no urine output, high blood sodium or chloride levels, or those in an alkaline state, as well as patients with heart block or severe myasthenia, should not use this medication. Administration should be avoided in patients receiving excessive fluid supply. Caution should be exercised in patients with severe acidosis, congestive heart failure or severe heart failure, edema due to sodium retention, hyperkalemia or potassium retention, and decreased renal function. Additionally, this product contains sodium metabisulfite, which can cause allergic reactions or asthmatic attacks, so caution is advised for asthmatic patients or those sensitive to sulfites. Skin rash may occur rarely due to hypersensitivity, and in such cases, administration should be stopped immediately. Symptoms such as nausea, vomiting, chest discomfort, palpitations, rapid heartbeat, and elevated blood pressure may occur. Rapid administration of large doses may result in acidosis, so caution is needed. Chills, fever, headache, dyspnea, shock, bronchospasm, and urinary tract spasms may also manifest. If magnesium is included, peripheral blood vessels may dilate. Metabolic abnormalities such as metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, osmotic diuresis, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiencies or excess, electrolyte imbalances, hyperammonemia in children, and metabolic alkalosis may occur. Patients with impaired liver or kidney function may experience increased blood urea nitrogen (BUN) levels, and in cases of severe liver dysfunction, serum amino acid imbalance, metabolic alkalosis, systemic nitrogen retention, hyperammonemia, and altered consciousness may manifest. Caution is required for electrolyte imbalances when administering large doses, especially when used in combination with electrolyte-containing solutions, as careful management of electrolyte balance is necessary. Excessive administration may lead to metabolic alkalosis, so solutions containing acid ions should be used with caution. Patients with kidney disease, lung disease, or severe cardiac disease should be administered this medication with caution while avoiding excessive fluid supply. Diabetic patients should monitor their blood glucose levels frequently during administration. Patients with hyponatremia, liver or kidney dysfunction should have individualized adjustments to their dosage, fluid balance, and serum electrolyte levels managed. This medication may interact with certain antibiotics or calcium salts, so any concurrent medications should be reported to the doctor or pharmacist. Pregnant women should only use this medication when the therapeutic benefits outweigh the risks, as its safety has not been established. In children, due to immature liver function, hyperammonemia may occur; thus, the administration concentration should be kept low, and blood ammonia levels should be checked frequently. In elderly patients, due to decreased bodily function, attention should be paid to slowing the administration rate and reducing the dosage. This medication contains electrolytes, so care must be taken regarding electrolyte balance with large doses, and the infusion rate should be slow. Rapid infusion may induce chills or vomiting and increase the loss of amino acids through the kidneys. The solution should be kept at body temperature, and strict aseptic conditions should be maintained during preparation. If the solution is cloudy or discolored, it should not be used, and storage should be limited to 24 hours in a refrigerator. If crystals form in the solution, they should be dissolved by warming and then cooled to body temperature for use. If there are any abnormalities in the packaging or container, it should not be used, and the condition of the solution should be checked before use.

Serious side effects

• Hives
• severe swelling (edema)
• chest tightness
• difficulty breathing
• shock
• asthmatic attacks
• dyspnea
• respiratory arrest
• elevated blood pressure
• liver failure

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid heartbeat
• elevated blood pressure
• acidosis
• chills
• fever

This medication may be sensitive to air and moisture, so it is important to store it in a sealed container at room temperature. This helps to maintain the effectiveness of the medication and prevent degradation.

Appearance

An injection solution that is colorless to light yellow and contained in a colorless transparent glass vial (for domestic use). An injection solution that is colorless to light yellow and contained in a transparent liquid in a polypropylene container (for export).

Package unit

For domestic use - 250 milliliters / bottle, For domestic use - 500 milliliters / bottle, For export - 200 milliliters / bag, For export - 250 milliliters / bag